Image credit: Volodymyr Hryshchenko, Unsplash
Infectious diseases remain a major global health threat, with bacteria, viruses, fungi, and parasites evolving resistance to conventional treatments. Antibiotics, antivirals, and antifungals have saved millions of lives, but the growing challenge of antimicrobial resistance (AMR) demands precise, innovative, and highly targeted therapies.1 Instead of traditional broad-spectrum drugs, researchers are now developing targeted treatments that selectively eliminate pathogens while minimizing harm to the body’s beneficial microbiome and reducing the risk of resistance.
This article delves deeper into three critical drug classes—phage therapy, antifungals, and Gram-negative antimicrobials—focusing on specific therapies currently in late-stage investigations or recently…